DPX from BioVaxys said about the wash and emulsion base Antigen Abgabe Systems an excessive functioning of the immune system

Vancouver, BC (ots/PRNewswire) –

Die Ergebnisse der Studie position das Unternehmen als Zielgruppe für Segmente des über 270 Million. USD schweren Markets for Arzneimittelverabreichungssysteme 1

VANCOUVER, BC, October 31, 2024 /PRNewswire/ – BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” oder das “Unternehmen”) has investigated the way in which this happens new immunological representation Verabreichungsplattform DPX einzigartige Untergruppen van Antigen-präsentierenden Zellen (“APCs” ) are recruited and activated, an immunogenicity of antigens that become used, and in the form of washes and emulsions based Antigen absorption systems that have a protective immunoactive effect.

These credit substances depend on the serious consequences of tumors of the anhaltenden antigen APCs, which active potent, antigen-specific zytotoxic T-Zellen. Der zeitige Methoden für Abbreichung von Peptideantigen umfassen interwoven Formulierungen on Wasserbasis, de een exposition van Peptide gegenüber Immunzellen ermöglichen, or oil-in-Wasser-Emulsionen, die wich a prolonger Peptideexposition beet, aber dysfunctional T-Zellen-Phanotypes could be reformed. The treatment with BioVaxys’ DPX technology is a non-wässrige, lipid-in-oil immunological therapeutic treatment with a widening platform, against the antigenic force and the injection system, which will be certain, if the DPX encapsulated force is activated. There is an active process that supports the APCs over time.

In a study done in Zusammenarbeit with the Dalhousie University of Halifax, Nova Scotia, over the years, DPX has worked with water and emulsion base formulations, a dynamic recruitment of immune cells and injection systems, the antigen digestion and the transport during the immune system claims . The immunotherapy and the antigen aufnahme and the injection system work with the Hilfe of the Multi-Parameter-Durchflusszytometry and the confocals Microscopy under the Verwendung of Modell-Peptidantigens, the Mäusen are varied, bewertet. Antigen-specific immunotherapy can be measured with an interferon-gamma (IFN-\u03b3)-based ELISpot-Test (Enzyme-Linked Immunospot), an IFN-\u03b3 messenger, which plays a separate role in the active functioning of the immune system. The ELISpot assay is an efficient method for the analysis of the Zellen, which occurs in response to an antigen-cytokine or antibody production.

“BioVaxys is one of the leading companies in the landscape of medical management,” said James Passin, CEO of BioVaxys, “These business development studies have improved our strategic position in a major segment of the billionaire markets for Medikamentenverabreichung. DPX does not eliminate the current losses due to antigen diversion, part of our inherent immune-activating properties, was a significant increase in potential in various market segments.”

The inconvenience of the study, the many forms that were in the low, lymphozytes and the injection system zurückzuhalten and did not follow any IFN-\u03b3-ELISpot-Reaktion auslösten. Thus, if DPX used the oil emulsion in the recruitment of APCs and the injection stelle and the active antigen-specific immunological überlegen, it would have a significant influence on the immunofiltration test two days after the DPX injection. An important significance of the DPX and oil file is that the antigen presentation is carried out by the DPX platform with an active action of more critical markers of T-Zell subsets as the emulsion. One of the most important and widely used things is the recruitment and action of the T-Zell group during the DPX war, which was antigenic as a force in the DPX war, but the DPX had all the immune system activating properties.

Kenneth Kovan, President and Chief Operating Officer at BioVaxys, says: “Knew that DPX is in the base of emulsions and proper formulas, which are one of the injectable verbs used in most of the world. This ergebnisse has the quantitative, qualitative and timely aspects of the Recruitment of Immunization by DPX and the establishment of a Verabreichungsplattformen reform and characteristic character of the DPX-Plattform Ausgelösten Immunantwort von de Aktivierung von T-Zell-Untergruppen mit intrinsically high Kapazität voor de Aufnahme, Presentatie und Aktivierung von Antigeneen.”

BioVaxys plant, available this month, see more details about the individual properties of DPX.

1 Drug Delivery Devices Market Size, Share and Trend Analysis Report by Application (Oncology, Infectious Diseases), by Route of Administration (Oral, Transdermal, Injectable), by End Use, by Region and Segment Forecasts, 2024 – 2030, Grand View Research

Information about BioVaxys Technology Corp.

BioVaxys Technology Corp. (www.biovaxys.com) is a biopharmaceutical drug in the clinical stadium, that is, patients with new immunotherapies are investigating their DPX immunotechnology technology platform and their research HapTenix©-“Neoantigen”-Tumorzellkonstrukt-Plattform basieren, een Krebserkrankungen, Infektionskrankheiten , Antigen desensitization in nahrungmittel allergies and other immunological diseases. During a different mechanism, the DPX platform is better able to support the immune system, a dedicated, robust and maintained immune system to heal. The Clinical Pipeline of the Unternehmens is equipped with Maveropepimut-S (MVP-S), based on the DPX platform and in Phase IIB of clinical development for the enhanced relapsed-refractory diffuse large B-Zell-Lymphoma (DLBCL) and platinum-resistant Eierstockkrebs is located. MVP-S loves antigenic Peptide from Survivin, a general known Krebsantigen, the enhanced Krebserkrankungen have an expressive effect, and a gentle effect on an activated immune system and a universe of CD4-T-Zell-Helfer-Peptid. MVP-S could extend and the more credit indications can have a clinically defined effect, so that active treatment can be carried out and a survival-specific anti-tumor immune virus can be applied. BioVaxys collaborates with DPX+SurMAGE, a dual soul-oriented immunotherapy, the antigen peptide for the Krebsprotein Survivin and MAGE-A9 combination, an immune system for both these uninterested Krebsantigene gleichzeitig auszulösen, DPX-RSV for Respiratory Syncytial Virus, DPX+rPA for the prophylaxis of erdnuss allergies and B V The BioVaxys pedigree has become one of the CSEs traded under the BIOV symbol and became one of the Frankfurter Börse (FRA: 5LB) and in the US (OTCQB: BVAXF). More information can be found at www.biovaxys.com and on X and LinkedIn.

IM NAMES OF THE PRIVATE

Caption “James Passin”

James Passin, CEO

Phone: +740 358 0555

Email: [email protected]

Warn in Bezug auf zkunftsgerichttete Informationen

This press conference has found the best “zukunftsgerichtete Informationen” und “zukunftsgerichttete Aussagen” (zusammenfassend “zukunftsgerichttete Aussagen”) in sin de die Kanadisch und American-US Wertvuurgesetze, based on the United States Private Securities Litigation Reform Act of 1995. All in this Enthaltenen Aussagen, met Ausnahme von Aussagen über historical Tatsachen, ohne Einschränkung, die sich auf die zukünftige betriebliche or finanzielle Leistung des Unternehmens beziehen, sind zukunftsgerichtte Aussagen. Zukunftsgerichtete Aussagen since häufig, aber nicht immer, an Worten wie “erwartet”, “antizipiert”, “glaubt”, “beabsichtigt”, “schätzt”, “potenziell”, “möglich” and ähnlichen Ausdrücken zu acknowledge, or an Aussagen, thats Ereignisse, beds or ergebnisse “eintreten were”, “können”, “könnten” or “sollten”. It cannot be guaranteed that it will be a problem if it is removed, and that the physical and mental health benefits could be removed from the defects, which were removed or implied in such cases.

These focused mirrors of the overarching, opinions and predictions of the tag broader, and the dem that Aussagen are empowered, and base on a reihe of Annahmen and Schätzungen, for all Annahme, that BioVaxys at the Entwicklung and Erprobung of Impfstoffen foutolgreich sein whole. These Annahmen en Schätzungen were vom Unternehmen zwar as vernünftig erachtetet, underliegen aber naturgemäß erheblichen geschäftlichen, economics, legal provisions, political and social Unsicherheiten and Unwägbarkeiten, darunter for allem, aber nicht ausschließlich, dem Risk, it is the implicit substance of BioVaxys that does not work and/or does not have the hereditary effect of the generic effect. When using the BioVaxys product there is a risk that the biotechnological products of the Entwicklung are interesting. If you are another doctor or sister, the Kapital of the clinical financing study, the fehlende treatment of external medicine, the university, with your products of long, complex and teuren processes of clinical studies and the new medical treatment, of your dying The market is being erforderlig ist, over the years, that Ungewissheit, ob seine autologous Zellimpfstoff-Immuntherapie can be developed in such a way that they will produce sichere and the same products, and, will die from the fall of his sollte, ob seine Impfstoffprodukte kommerziell akzeptiert zijn en rent sin, de Ausgaben, Verzögerungen, Ungewissheiten und Komplikationen, met den biopharmazeutische Unternehmen in der Entwicklungsphase typicalerweise konfrontiert sind, finanzielle und entwicklungsbezogene Verpflichtungen im Rahmen von Lizenzvereinbarungen, um ihre Rechte an ihren Products und Technologies zu Schützen, the Erlangung und der Schutz new propertyrecht and the Vermeidung von Verletzungen by Dritte sowie ihre Abhängigkeit von der Herstellung by Dritte.

If there is no representation whatsoever, the targeted spend, the analysis, the forecasts or other factors that are done will be such that these things happen, that is the way they are done.

Logo – https://mma.prnewswire.com/media/2415135/4999130/BioVaxys_Technology_Corp_Logo.jpg

View original content: https://www.prnewswire.com/de/pressemitteilungen/dpx-von-biovaxys-zeigt-im-vergleich-zu-wassrigen-und-emulsionsbasierten-antigenabgabesystemen-eine-uberlege-aktivierung-des-immunsystems- 302293451.html

Original content from: BioVaxys Technology Corp., added to the news
Original notification: https://www.presseportal.de/pm/153148/5899492